USA

Ubrogepant safety and efficacy data from 106 patients treated at a tertiary headache centre in the USA support previous clinical trial findings. In at least 75% of treated attacks, 19% of patients reported headache freedom two hours after treatment, and 48% reported headache relief. These data compare with 19% and 21% of patients in ACHIEVE …

US data collected from a single New York state centre between May 2018 and September 2019 have shown that erenumab, fremanezumab and galcanezumab were well tolerated in patients with chronic migraine at six months follow up, and reduced severe migraine days. The 77 patients were prescribed 90 treatment trials of a CGRP monoclonal antibody, and patient-reported …

Real world data from a tertiary headache clinic in the USA suggest that more research is needed to identify likely responders to erenumab in complex patient populations. In a retrospective, observational study of 101 patients (95 with chronic migraine, five with episodic migraine and 19 with medication overuse headache) who received at least one erenumab …

At a headache centre in Rochester, erenumab more than halved migraine frequency after three months of treatment in patients with refractory chronic migraine who had previously failed at least three classes of preventive medication, or were currently using preventive agents including botulinum toxin. Preliminary results from a study of 93 patients, most of whom had …